285 related articles for article (PubMed ID: 11948419)
1. Motif analysis of the tumor suppressor gene MMAC/PTEN identifies tyrosines critical for tumor suppression and lipid phosphatase activity.
Koul D; Jasser SA; Lu Y; Davies MA; Shen R; Shi Y; Mills GB; Yung WK
Oncogene; 2002 Apr; 21(15):2357-64. PubMed ID: 11948419
[TBL] [Abstract][Full Text] [Related]
2. Suppression of matrix metalloproteinase-2 gene expression and invasion in human glioma cells by MMAC/PTEN.
Koul D; Parthasarathy R; Shen R; Davies MA; Jasser SA; Chintala SK; Rao JS; Sun Y; Benvenisite EN; Liu TJ; Yung WK
Oncogene; 2001 Oct; 20(46):6669-78. PubMed ID: 11709701
[TBL] [Abstract][Full Text] [Related]
3. Adenoviral-mediated expression of MMAC/PTEN inhibits proliferation and metastasis of human prostate cancer cells.
Davies MA; Kim SJ; Parikh NU; Dong Z; Bucana CD; Gallick GE
Clin Cancer Res; 2002 Jun; 8(6):1904-14. PubMed ID: 12060635
[TBL] [Abstract][Full Text] [Related]
4. In vivo gene therapy of human bladder cancer with PTEN suppresses tumor growth, downregulates phosphorylated Akt, and increases sensitivity to doxorubicin.
Tanaka M; Grossman HB
Gene Ther; 2003 Sep; 10(19):1636-42. PubMed ID: 12923562
[TBL] [Abstract][Full Text] [Related]
5. Adenoviral transgene expression of MMAC/PTEN in human glioma cells inhibits Akt activation and induces anoikis.
Davies MA; Lu Y; Sano T; Fang X; Tang P; LaPushin R; Koul D; Bookstein R; Stokoe D; Yung WK; Mills GB; Steck PA
Cancer Res; 1998 Dec; 58(23):5285-90. PubMed ID: 9850049
[TBL] [Abstract][Full Text] [Related]
6. Regulation of cell migration by the C2 domain of the tumor suppressor PTEN.
Raftopoulou M; Etienne-Manneville S; Self A; Nicholls S; Hall A
Science; 2004 Feb; 303(5661):1179-81. PubMed ID: 14976311
[TBL] [Abstract][Full Text] [Related]
7. The tumour-suppressor function of PTEN requires an N-terminal lipid-binding motif.
Walker SM; Leslie NR; Perera NM; Batty IH; Downes CP
Biochem J; 2004 Apr; 379(Pt 2):301-7. PubMed ID: 14711368
[TBL] [Abstract][Full Text] [Related]
8. Interaction of the tumor suppressor PTEN/MMAC with a PDZ domain of MAGI3, a novel membrane-associated guanylate kinase.
Wu Y; Dowbenko D; Spencer S; Laura R; Lee J; Gu Q; Lasky LA
J Biol Chem; 2000 Jul; 275(28):21477-85. PubMed ID: 10748157
[TBL] [Abstract][Full Text] [Related]
9. Stabilization and productive positioning roles of the C2 domain of PTEN tumor suppressor.
Georgescu MM; Kirsch KH; Kaloudis P; Yang H; Pavletich NP; Hanafusa H
Cancer Res; 2000 Dec; 60(24):7033-8. PubMed ID: 11156408
[TBL] [Abstract][Full Text] [Related]
10. Acute regulation of the tumour suppressor phosphatase, PTEN, by anionic lipids and reactive oxygen species.
Downes CP; Walker S; McConnachie G; Lindsay Y; Batty IH; Leslie NR
Biochem Soc Trans; 2004 Apr; 32(Pt 2):338-42. PubMed ID: 15046604
[TBL] [Abstract][Full Text] [Related]
11. PTEN decreases in vivo vascularization of experimental gliomas in spite of proangiogenic stimuli.
Abe T; Terada K; Wakimoto H; Inoue R; Tyminski E; Bookstein R; Basilion JP; Chiocca EA
Cancer Res; 2003 May; 63(9):2300-5. PubMed ID: 12727853
[TBL] [Abstract][Full Text] [Related]
12. Pten signaling in gliomas.
Knobbe CB; Merlo A; Reifenberger G
Neuro Oncol; 2002 Jul; 4(3):196-211. PubMed ID: 12084351
[TBL] [Abstract][Full Text] [Related]
13. Analysis of the cellular functions of PTEN using catalytic domain and C-terminal mutations: differential effects of C-terminal deletion on signalling pathways downstream of phosphoinositide 3-kinase.
Leslie NR; Gray A; Pass I; Orchiston EA; Downes CP
Biochem J; 2000 Mar; 346 Pt 3(Pt 3):827-33. PubMed ID: 10698713
[TBL] [Abstract][Full Text] [Related]
14. Regulation of Akt/PKB activity, cellular growth, and apoptosis in prostate carcinoma cells by MMAC/PTEN.
Davies MA; Koul D; Dhesi H; Berman R; McDonnell TJ; McConkey D; Yung WK; Steck PA
Cancer Res; 1999 Jun; 59(11):2551-6. PubMed ID: 10363971
[TBL] [Abstract][Full Text] [Related]
15. Inactivation of platelet-derived growth factor receptor by the tumor suppressor PTEN provides a novel mechanism of action of the phosphatase.
Mahimainathan L; Choudhury GG
J Biol Chem; 2004 Apr; 279(15):15258-68. PubMed ID: 14718524
[TBL] [Abstract][Full Text] [Related]
16. Activation of synovial fibroblasts in rheumatoid arthritis: lack of Expression of the tumour suppressor PTEN at sites of invasive growth and destruction.
Pap T; Franz JK; Hummel KM; Jeisy E; Gay R; Gay S
Arthritis Res; 2000; 2(1):59-64. PubMed ID: 11219390
[TBL] [Abstract][Full Text] [Related]
17. PTEN gene therapy induces growth inhibition and increases efficacy of chemotherapy in prostate cancer.
Tanaka M; Rosser CJ; Grossman HB
Cancer Detect Prev; 2005; 29(2):170-4. PubMed ID: 15829377
[TBL] [Abstract][Full Text] [Related]
18. Binding of PTEN to specific PDZ domains contributes to PTEN protein stability and phosphorylation by microtubule-associated serine/threonine kinases.
Valiente M; Andrés-Pons A; Gomar B; Torres J; Gil A; Tapparel C; Antonarakis SE; Pulido R
J Biol Chem; 2005 Aug; 280(32):28936-43. PubMed ID: 15951562
[TBL] [Abstract][Full Text] [Related]
19. The PTEN lipid phosphatase domain is not required to inhibit invasion of glioma cells.
Maier D; Jones G; Li X; Schönthal AH; Gratzl O; Van Meir EG; Merlo A
Cancer Res; 1999 Nov; 59(21):5479-82. PubMed ID: 10554022
[TBL] [Abstract][Full Text] [Related]
20. The complexity of PTEN: mutation, marker and potential target for therapeutic intervention.
Steelman LS; Bertrand FE; McCubrey JA
Expert Opin Ther Targets; 2004 Dec; 8(6):537-50. PubMed ID: 15584861
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
